# Open-Label Safety Study of Solriamfetol in Subjects With Binge Eating Disorder

> **NCT06878976** · PHASE3 · ENROLLING_BY_INVITATION · sponsor: **Axsome Therapeutics, Inc.** · enrollment: 300 (estimated)

## Conditions studied

- Binge-Eating Disorder

## Interventions

- **DRUG:** Solriamfetol 75mg, 150 mg, or 300 mg

## Key facts

- **NCT ID:** NCT06878976
- **Lead sponsor:** Axsome Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-02-20
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2025-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06878976

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06878976, "Open-Label Safety Study of Solriamfetol in Subjects With Binge Eating Disorder". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT06878976. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*